

Christopher C Rowe

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9053112/christopher-c-rowe-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237
papers

27,316
citations

63
h-index

164
g-index

336
ext. papers

33,479
ext. citations

5.9
avg, IF

6.54
L-index

#	Paper	IF	Citations
237	Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 280-92	1.2	4210
236	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 535-562	1.2	3155
235	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
234	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology, The</i> , 2013 , 12, 357-67	24.1	1336
233	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
232	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
231	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15056	51.1	755
230	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010 , 31, 1275-83	5.6	750
229	High performance plasma amyloid- β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018 , 554, 249-254	50.4	733
228	Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007 , 130, 2837-44	11.2	657
227	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011 , 69, 181-92	9.4	576
226	Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology, The</i> , 2008 , 7, 129-35	24.1	551
225	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009 , 21, 672-87	3.4	506
224	Tau imaging: early progress and future directions. <i>Lancet Neurology, The</i> , 2015 , 14, 114-24	24.1	360
223	The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1-15.e1-4	1.2	355
222	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2013 , 9, e-1-16	1.2	330
221	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 964-74	1.2	288

220	Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1210-7	8.9	267
219	Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010 , 67, 317-24	9.4	255
218	18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. <i>Brain</i> , 2011 , 134, 1089-100	11.2	255
217	Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β amyloid imaging. <i>Brain</i> , 2011 , 134, 3030-43	11.2	243
216	Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018 , 14, 225-236	15	211
215	Brain amyloid imaging. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1733-40	8.9	184
214	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 476-90	8.9	179
213	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012 , 135, 2126-39	11.2	179
212	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , 2013 , 81, 487-500	6.5	173
211	Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 547-52	8.9	172
210	Predicting Alzheimer disease with β amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013 , 74, 905-13	9.4	158
209	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014 , 137, 221-31	11.2	145
208	Cerebral quantitative susceptibility mapping predicts amyloid- β -related cognitive decline. <i>Brain</i> , 2017 , 140, 2112-2119	11.2	144
207	Comparison of 11C-PiB and 18F-florbetaben for A β imaging in ageing and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 983-9	8.8	143
206	Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. <i>Frontiers in Neurology</i> , 2014 , 4, 205	4.1	140
205	Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2018 , 141, 888-902	11.2	139
204	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 816-26	8.8	137
203	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , <i>The</i> , 2016 , 15, 1044-53	24.1	135

202	High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. <i>Archives of Neurology</i> , 2009 , 66, 1537-44		133
201	In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. <i>Journal of Neuroscience</i> , 2007 , 27, 10365-71	6.6	130
200	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. <i>Neuropsychologia</i> , 2011 , 49, 2384-90	3.2	126
199	Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β amyloid imaging in aging and dementia. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 880-6	8.9	121
198	Amyloid- β anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. <i>JAMA Psychiatry</i> , 2015 , 72, 284-91	14.5	114
197	Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011 , 134, 798-807	11.2	113
196	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010 , 133, 3349-58	5.2	111
195	Sex, amyloid, and APOE ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1193-1203	1.2	111
194	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014 , 82, 1266-73	6.5	110
193	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 796-804	1.2	102
192	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
191	Beta-amyloid imaging with florbetaben. <i>Clinical and Translational Imaging</i> , 2015 , 3, 13-26	2	93
190	BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2457-64	5.6	93
189	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012 , 34, 345-58	2.1	92
188	Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012 , 79, 1645-52	6.5	84
187	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 205-216	1.2	82
186	The ART of loss: A β imaging in the evaluation of Alzheimer's disease and other dementias. <i>Molecular Neurobiology</i> , 2008 , 38, 1-15	6.2	81
185	Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1472-8	8.9	79

184	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016 , 39, 1063-8	1.1	76
183	Characterization of PiB binding to white matter in Alzheimer disease and other dementias. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 198-204	8.9	76
182	AAmyloid and Tau Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2017 , 47, 75-88	5.4	72
181	Biochemically-defined pools of amyloid- β in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017 , 140, 1486-1498	11.2	70
180	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015 , 36 Suppl 1, S159-66	5.6	70
179	Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013 , 28, 320-30	2.7	70
178	Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 309-15	8.9	69
177	Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. <i>Archives of Neurology</i> , 2007 , 64, 1140-4		64
176	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. <i>Neurobiology of Aging</i> , 2015 , 36, 1231-8	5.6	63
175	AAmyloid imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 431-6	5.5	63
174	Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015 , 7, 105-13	5.3	63
173	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 11	9	62
172	AAmyloid and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 743-751.e1	1.2	62
171	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain AAmyloid burden. <i>Translational Psychiatry</i> , 2018 , 8, 47	8.6	59
170	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1565-1571	1.2	59
169	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 965-992	4.3	57
168	Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 661-8	4.3	57
167	Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. <i>PLoS ONE</i> , 2014 , 9, e86498	3.7	57

166	APOE ϵ moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 1239-44	5.6	56
165	F-Florbetaben PET beta-amyloid binding expressed in Centiloids. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2053-2059	8.8	55
164	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 2, 19-26	5.2	54
163	Amyloid-related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 677-86	4.3	54
162	Standardized Expression of 18F-NAV4694 and 11C-PiB β Amyloid PET Results with the Centiloid Scale. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1233-7	8.9	52
161	Association of β Amyloid and Apolipoprotein E ϵ With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018 , 75, 488-494	17.2	51
160	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 622-635	6	51
159	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. <i>BMC Bioinformatics</i> , 2014 , 15 Suppl 16, S11	3.6	49
158	Implementing the centiloid transformation for C-PiB and β amyloid F-PET tracers using CapAIBL. <i>NeuroImage</i> , 2018 , 183, 387-393	7.9	47
157	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014 , 83, 1345-52	6.5	46
156	β Amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013 , 9, 538-45	1.2	45
155	In vitro characterization of [18F]-florbetaben, an β imaging radiotracer. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 1042-8	2.1	45
154	Amyloid imaging with PET in early Alzheimer disease diagnosis. <i>Medical Clinics of North America</i> , 2013 , 97, 377-98	7	45
153	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016 , 139, 2528-39	11.2	45
152	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44
151	(18)F-florbetaben β imaging in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 4	9	40
150	Subjective Memory Complaints in APOE ϵ 4 Carriers are Associated with High Amyloid- β Burden. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 1115-22	4.3	40
149	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 22	9	39

148	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017 , 7, 9766	4.9	38
147	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 175-87	4.3	38
146	Clinical profile of PiB-positive corticobasal syndrome. <i>PLoS ONE</i> , 2013 , 8, e61025	3.7	38
145	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 455-463	3.9	36
144	Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and A β accumulation in cognitively normal older adults and adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015 , 30, 49-58	2.7	35
143	Optimal Reference Region to Measure Longitudinal Amyloid- β Change with F-Florbetaben PET. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1300-1306	8.9	34
142	Decline in cognitive function over 18 months in healthy older adults with high amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 861-71	4.3	34
141	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015 , 11, 850-9	1.2	33
140	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 354-361	3.3	33
139	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. <i>Neuropsychology</i> , 2015 , 29, 571-81	3.8	33
138	Relationship between memory performance and β amyloid deposition at different stages of Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2012 , 10, 141-4	2.3	33
137	Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. <i>PLoS ONE</i> , 2013 , 8, e58816	3.7	33
136	Centiloid scaling for quantification of brain amyloid with [F]flutemetamol using multiple processing methods. <i>EJNMMI Research</i> , 2018 , 8, 107	3.6	33
135	Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 627-37	4.3	31
134	Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. <i>Neurodegenerative Diseases</i> , 2012 , 10, 161-5	2.3	31
133	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012 , 24, 197-204	3.4	31
132	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014 , 26, 543-54	3.4	30
131	Cognitive decline in adults with amnesic mild cognitive impairment and high amyloid- β prodromal Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 1167-76	4.3	30

130	Cognitive consequences of high A β amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. <i>Neuropsychology</i> , 2013 , 27, 322-332	3.8	30
129	Assessment of amyloid τ in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 9, 10-20	5.2	29
128	MR-less surface-based amyloid assessment based on 11C PiB PET. <i>PLoS ONE</i> , 2014 , 9, e84777	3.7	29
127	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A β serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018 , 14, 43-53	1.2	28
126	Positron Emission Tomographic Imaging in Stroke: Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke. <i>Stroke</i> , 2016 , 47, 113-9	6.7	28
125	A β -related memory decline in APOE ϵ noncarriers: Implications for Alzheimer disease. <i>Neurology</i> , 2016 , 86, 1635-42	6.5	28
124	Prediction of amyloid- β pathology in amnesic mild cognitive impairment with neuropsychological tests. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 451-62	4.3	27
123	Comparison of F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 807-816	1.2	26
122	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 1293-1302	4.3	25
121	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. <i>Computerized Medical Imaging and Graphics</i> , 2015 , 46 Pt 3, 269-76	7.6	24
120	Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. <i>Neurology</i> , 2016 , 87, 1093-101	6.5	23
119	Amyloid imaging in Alzheimer's disease and other dementias. <i>Brain Imaging and Behavior</i> , 2009 , 3, 246-61.1	4.1	23
118	Amyloid imaging. <i>International Psychogeriatrics</i> , 2011 , 23 Suppl 2, S41-9	3.4	23
117	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 5698	17.4	23
116	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 1079-89	4.3	22
115	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014 , 204, 400-1	5.4	22
114	Concordance of Text Message Ecological Momentary Assessment and Retrospective Survey Data Among Substance-Using Men Who Have Sex With Men: A Secondary Analysis of a Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2016 , 4, e44	5.5	22
113	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ -positive cognitively normal adults with high A β amyloid burden. <i>Scientific Reports</i> , 2018 , 8, 2034	4.9	21

112	The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013 , 25, 1667-77	3.4	21
111	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ϵ and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015 , 10, e0139082	3.7	20
110	Amyloid PET Ligands for Dementia. <i>PET Clinics</i> , 2010 , 5, 33-53	2.2	20
109	Klotho allele status is not associated with A β and APOE ϵ -related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 76, 162-165	5.6	19
108	18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1547-53	8.9	19
107	Long night's journey into the day: amyloid- β imaging in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 33 Suppl 1, S349-59	4.3	19
106	Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, 21-30	3.1	18
105	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12005	5.2	17
104	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017 , 2017, 7935406	2	17
103	Automated (11)C-PiB standardized uptake value ratio. <i>Academic Radiology</i> , 2008 , 15, 1376-89	4.3	17
102	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 16	9	16
101	Research and standardization in Alzheimer's trials: reaching international consensus. <i>Alzheimer's and Dementia</i> , 2013 , 9, 160-8	1.2	16
100	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , 2019 , 85, 241-250	9.4	16
99	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1193-1211	4.3	16
98	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 1299-1305	4.3	16
97	A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. <i>Scientific Reports</i> , 2017 , 7, 44368	4.9	15
96	Impact of APOE- ϵ carriage on the onset and rates of neocortical A β amyloid deposition. <i>Neurobiology of Aging</i> , 2020 , 95, 46-55	5.6	15
95	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018 , 229, 269-274	6.6	15

94	Amyloid β -Associated cognitive decline in the absence of clinical disease progression and systemic illness. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 156-164	5.2	15
93	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017 , 13, 388-398	1.2	15
92	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021 , 5, 443-468	3.3	15
91	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. <i>International Psychogeriatrics</i> , 2017 , 29, 1825-1834	3.4	14
90	The Women's Healthy Ageing Project: fertile ground for investigation of healthy participants 'at risk' for dementia. <i>International Review of Psychiatry</i> , 2013 , 25, 726-37	3.6	14
89	11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 423-8	4.3	14
88	Plasma Amyloid- β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1057-1065	4.3	14
87	Relationship Between Amyloid- β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 1313-1325	4.3	14
86	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 977-988	4.3	13
85	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012 , 205, 96-109	3	13
84	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 362-370	3.3	13
83	Rates of age- and amyloid β -Associated cortical atrophy in older adults with superior memory performance. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 566-575	5.2	12
82	Management impact of FDG-PET in dementia: results from a tertiary center memory clinic. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 885-92	4.3	12
81	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 897-907	4.3	12
80	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β -negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021 , 97, 41-48	5.6	12
79	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β -Associated Cognitive Decline in Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2019 , 34, 585-598	2.7	11
78	Advances in molecular imaging for the diagnosis of dementia. <i>Expert Opinion on Medical Diagnostics</i> , 2009 , 3, 705-16		11
77	Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 611-617	4.3	11

76	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 423	5.3	11
75	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 70, 170-179	5.6	10
74	Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform 2014 ,		10
73	Tau imaging with PET: an overview of challenges, current progress, and future applications. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 61, 405-413	1.4	10
72	Association of β Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021 , 96, e662-e670	6.5	10
71	In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. <i>NeuroImage: Clinical</i> , 2020 , 28, 102479	5.3	10
70	Advances in Brain Amyloid Imaging. <i>Seminars in Nuclear Medicine</i> , 2021 , 51, 241-252	5.4	10
69	APOE ϵ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 411-422	4.3	9
68	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 193-201	4.3	9
67	Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 551-61	4.3	9
66	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
65	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. <i>Scientific Reports</i> , 2019 , 9, 17069	4.9	9
64	Plasma transferrin and hemopexin are associated with altered A β uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 72	9	8
63	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018 , 7-8, 14-20	1.1	8
62	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018 , 70, 22-29	3	8
61	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2225-2232	8.8	8
60	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 303-315	4.3	7
59	Longitudinal evaluation of the natural history of amyloid- β in plasma and brain. <i>Brain Communications</i> , 2020 , 2, fcaa041	4.5	6

58	Head-to-head comparison of cerebral blood flow single-photon emission computed tomography and F-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease. <i>Internal Medicine Journal</i> , 2021 , 51, 1243-1250	1.6	5
57	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. <i>Lecture Notes in Computer Science</i> , 2016 , 109-116	0.9	5
56	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 614-619	8.9	5
55	val158met is not associated with A β amyloid and β related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019 , 6, 147-152	2	4
54	Imago Mundi, Imago AD, Imago ADNI. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 62	9	4
53	Automatic detection of small spherical lesions using multiscale approach in 3D medical images 2013 ,		4
52	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014 , 26, 1737-46	3.4	4
51	Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation 2011 ,		4
50	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study. <i>Psychological Assessment</i> , 2018 , 30, 1308-1316	5.3	4
49	Early detection of amyloid load using F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 67	9	4
48	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e1632-e1645	6.5	4
47	Self-reported confusion is related to global and regional A β amyloid: data from the Women's healthy ageing project. <i>Brain Imaging and Behavior</i> , 2018 , 12, 78-86	4.1	3
46	Divergent Network Patterns of Amyloid- β Deposition in Logopenic and Amnesic Alzheimer's Disease Presentations. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016 , 1, 24-31	3.4	3
45	IC-O301: The Centiloid Scale: Standardization of amyloid imaging measures 2013 , 9, P8-P8		3
44	Advances in structural and molecular neuroimaging in Alzheimer's disease. <i>Medical Journal of Australia</i> , 2011 , 194, S20-3	4	3
43	Quantitative approaches to amyloid imaging. <i>Methods in Molecular Biology</i> , 2011 , 680, 201-25	1.4	3
42	In vivo microstructural heterogeneity of white matter lesions in Alzheimer's disease using tissue compositional analysis of diffusion MRI data		3
41	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2183-2199	8.8	3

40	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 146-157	3.1	3
39	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. <i>NeuroImage</i> , 2021 , 226, 117593	7.9	3
38	Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?. <i>Brain</i> , 2018 , 141, e45	11.2	2
37	APOE ϵ resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
36	Human biodistribution and internal dosimetry of 4-[F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart. <i>EJNMMI Research</i> , 2020 , 10, 61	3.6	2
35	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 321-334	4.3	2
34	O2-08-02: The Tau Meter Scale for the Generation of Continuous and Categorical Measures of Tau Deposits in the Brain: Results from 18F-AV1451 and 18F-THK5351 Tau Imaging Studies 2016 , 12, P244-P244		2
33	PET Imaging of brain muscarinic receptors with F-Fluorobenzyl-Dexetimide: A first in human study. <i>Psychiatry Research - Neuroimaging</i> , 2021 , 316, 111354	2.9	2
32	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12307	5.2	2
31	O1-01-04: A β accumulation in non-demented individuals: A longitudinal F-18-flutemetamol study 2015 , 11, P125-P125		1
30	Alzheimer's disease detection using 11C-PiB with improved partial volume effect correction 2009 ,		1
29	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12226		1
28	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020 , 731, 135078	3.3	1
27	Amyloid- β Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 163-173	4.3	1
26	Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study. <i>BMJ Open</i> , 2020 , 10, e038312	3	1
25	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. <i>Hormones and Behavior</i> , 2021 , 131, 104966	3.7	1
24	Untangling tau imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 4, 39-42	5.2	1
23	Is Associated with Amyloid- β and β -Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021 , 5, 111-120	3.3	1

22	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 771214	5.3	1
21	Mesial temporal tau in amyloid-negative cognitively normal older persons.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 51	9	1
20	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022 , 10, 1045	4.8	1
19	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid- β . <i>Neurobiology of Disease</i> , 2022 , 105783	7.5	1
18	Does cognitive decline occur decades after moderate to severe traumatic brain injury? A prospective controlled study. <i>Neuropsychological Rehabilitation</i> , 2021 , 1-20	3.1	0
17	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 2 moderates the association between insulin resistance and increased CSF tau levels.. <i>Neurobiology of Aging</i> , 2022 , 114, 38-48	5.6	0
16	Quantitative thresholds for 18F-florbetaben PET for the detection of low amyloid load. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042933	1.2	
15	One year tau progression measured with F-18 MK6240 PET. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044987.2	1.2	
14	Basal forebrain atrophy and tau pathology are correlated in prodromal AD. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046111	1.2	
13	O3-07-01: AMYLOID RELATED COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE IS MODERATED BY APOE AND BDNF POLYMORPHISMS 2014 , 10, P221-P221		
12	P1-145: Implementation of the centiloid transformation for F-18 nav4694: Comparison with PiB 2015 , 11, P398-P398		
11	O40701: Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL) 2013 , 9, P695-P695		
10	[S20102]: COMPARISON OF DIFFERENT TAU PET TRACERS AND THEIR RELATIONSHIP TO AMYLOID 2017 , 13, P541-P541		
9	[P2B89]: LONGITUDINAL ASSESSMENT OF A β ACCUMULATION WITH FLUTEMETAMOL 2017 , 13, P778-P778		
8	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study 2011 , 7, S6-S6		
7	A β imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions 2021 , 283-343		
6	A β imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions 2014 , 213-254		
5	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1039-1052	4.3	

4	P2-364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [F-18]-MK6240, A SECOND GENERATION SELECTIVE TAU TRACER 2018 , 14, P831-P832	
3	O2-06-05: CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER'S DISEASE 2018 , 14, P634-P634	
2	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022 , 48674221081773	2.6
1	Brain age in chronic traumatic brain injury.. <i>NeuroImage: Clinical</i> , 2022 , 35, 103039	5.3